Enolase deficiency

Enolase deficiency
Enolase deficiency
Specialty	Endocrinology

Last updated June 20, 2024

Enolase deficiency is a rare genetic disorder of glucose metabolism. Partial deficiencies have been observed in several caucasian families. The deficiency is transmitted through an autosomal dominant inheritance pattern.^[1] The gene for enolase 1 has been localized to chromosome 1 in humans.^[2] Enolase deficiency, like other glycolytic enzyme deficiences, usually manifests in red blood cells as they rely entirely on anaerobic glycolysis. Enolase deficiency is associated with a spherocytic phenotype and can result in hemolytic anemia, which is responsible for the clinical signs of Enolase deficiency.^[3]

Symptoms

Symptoms of enolase deficiency include exercise-induced myalgia and generalized muscle weakness and fatigability, both with onset in adulthood. Symptoms also include muscle pain without cramps, and decreased ability to sustain long term exercise.^[4]

Causes

Genetics is found to be the cause of enolase deficiency. The individual in the first known case of this deficiency was heterozygous for the gene for β-enolase, and carried two missense mutations, one inherited from each parent. His muscle cells synthesized two forms of β-enolase, each carrying a different mutation. These mutations changed glycine at position 374 to glutamate (G374E) and glycine at position 156 to aspartate (G156D).^[4]

Pathophysiology

The enolase enzyme catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate; this is the ninth step in glycolysis. Enolase is a dimeric protein formed from three subunits, α, β, and γ, encoded by different genes. The αα homodimer assumes all enolase activity in the early stages of embryo development and in some adult tissues. In tissues that need large amounts of energy, the αγ and γγ in the brain, and αβ and ββ in striated muscles these forms of enolase are present. At all stages of development, β-enolase expression is only found in striated muscles. In adult humans, the ββ homodimer accounts for more than 90% of total enolase activity in muscle.

Two mutations in the ENO3 gene, the gene encoding β-enolase, is responsible for the deficiency, both mutations changed highly conserved amino acid residues. One of the changes was of a glycine residue at position 374 to aspartate, this amino acid change was located in close proximity to the His residue of human enolase, which is an important part of the β-enolase catalytic site, while the glycine at position 156 changed to glutamate, which may have brought about change the secondary structure of the enzyme. These mutations may impair activity by significantly reducing the steady- state level of the protein, rather than produce a non- functional mutant protein. Mutations of the β-enolase dimer complexes might result in incorrect folding and increased susceptibility to protein degradation thus causing the deficiency.^[4]

Similar mutations on yeast showed destabilization of the protein and decreased substrate affinity. Destabilization of the protein results in partial dissociation, some researchers propose that in muscle cells this dissociation may be perceived as an abnormality leading to degradation of the mutated enolase.^[5]

Diagnosis

Treatment

Related Research Articles

<span class="mw-page-title-main">Aminolevulinic acid synthase</span> Class of enzymes

Aminolevulinic acid synthase (ALA synthase, ALAS, or delta-aminolevulinic acid synthase) is an enzyme (EC 2.3.1.37) that catalyzes the synthesis of δ-aminolevulinic acid (ALA) the first common precursor in the biosynthesis of all tetrapyrroles such as hemes, cobalamins and chlorophylls. The reaction is as follows:

Phosphofructokinase deficiency is a rare muscular metabolic disorder, with an autosomal recessive inheritance pattern.

Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells. Both autosomal dominant and recessive inheritance have been observed with the disorder; classically, and more commonly, the inheritance is autosomal recessive. Pyruvate kinase deficiency is the second most common cause of enzyme-deficient hemolytic anemia, following G6PD deficiency.

Aldolase A, also known as fructose-bisphosphate aldolase, is an enzyme that in humans is encoded by the ALDOA gene on chromosome 16.

Glucose-6-phosphate dehydrogenase (G6PD or G6PDH) (EC 1.1.1.49) is a cytosolic enzyme that catalyzes the chemical reaction

Phosphopyruvate hydratase, usually known as enolase, is a metalloenzyme (EC 4.2.1.11) that catalyses the conversion of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP), the ninth and penultimate step of glycolysis. The chemical reaction is:

Phosphoglycerate kinase is an enzyme that catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate (1,3-BPG) to ADP producing 3-phosphoglycerate (3-PG) and ATP :

Hexosaminidase is an enzyme involved in the hydrolysis of terminal N-acetyl-D-hexosamine residues in N-acetyl-β-D-hexosaminides.

Glutathione synthetase deficiency (GSD) is a rare autosomal recessive metabolic disorder that prevents the production of glutathione. Glutathione helps prevent damage to cells by neutralizing harmful molecules generated during energy production. Glutathione also plays a role in processing medications and cancer-causing compounds (carcinogens), and building DNA, proteins, and other important cellular components.

<span class="mw-page-title-main">Aldolase A deficiency</span> Medical condition

Aldolase A deficiency is an autosomal recessive metabolic disorder resulting in a deficiency of the enzyme aldolase A; the enzyme is found predominantly in red blood cells and muscle tissue. The deficiency may lead to hemolytic anaemia as well as myopathy associated with exercise intolerance and rhabdomyolysis in some cases.

<span class="mw-page-title-main">Transaldolase</span> Enzyme family

Transaldolase is an enzyme of the non-oxidative phase of the pentose phosphate pathway. In humans, transaldolase is encoded by the TALDO1 gene.

Enolase 1 (ENO1), more commonly known as alpha-enolase, is a glycolytic enzyme expressed in most tissues, one of the isozymes of enolase. Each isoenzyme is a homodimer composed of 2 alpha, 2 gamma, or 2 beta subunits, and functions as a glycolytic enzyme. Alpha-enolase, in addition, functions as a structural lens protein (tau-crystallin) in the monomeric form. Alternative splicing of this gene results in a shorter isoform that has been shown to bind to the c-myc promoter and function as a tumor suppressor. Several pseudogenes have been identified, including one on the long arm of chromosome 1. Alpha-enolase has also been identified as an autoantigen in Hashimoto encephalopathy.

Hexokinase-1 (HK1) is an enzyme that in humans is encoded by the HK1 gene on chromosome 10. Hexokinases phosphorylate glucose to produce glucose-6-phosphate (G6P), the first step in most glucose metabolism pathways. This gene encodes a ubiquitous form of hexokinase which localizes to the outer membrane of mitochondria. Mutations in this gene have been associated with hemolytic anemia due to hexokinase deficiency. Alternative splicing of this gene results in five transcript variants which encode different isoforms, some of which are tissue-specific. Each isoform has a distinct N-terminus; the remainder of the protein is identical among all the isoforms. A sixth transcript variant has been described, but due to the presence of several stop codons, it is not thought to encode a protein. [provided by RefSeq, Apr 2009]

Glutamate–cysteine ligase catalytic subunit is an enzyme that in humans is encoded by the GCLC gene.

Cytosolic 5'-nucleotidase 3 (NTC53), also known as cytosolic 5'-nucleotidase 3A, pyrimidine 5’-nucleotidase, and p56, is an enzyme that in humans is encoded by the NT5C3, or NT5C3A, gene on chromosome 7.

Enolase 3 (ENO3), more commonly known as beta-enolase (ENO-β), is an enzyme that in humans is encoded by the ENO3 gene.

Pyruvate kinase PKLR is an enzyme that in humans is encoded by the PKLR gene.

Triosephosphate isomerase is an enzyme that in humans is encoded by the TPI1 gene.

Human genetic resistance to malaria refers to inherited changes in the DNA of humans which increase resistance to malaria and result in increased survival of individuals with those genetic changes. The existence of these genotypes is likely due to evolutionary pressure exerted by parasites of the genus Plasmodium which cause malaria. Since malaria infects red blood cells, these genetic changes are most common alterations to molecules essential for red blood cell function, such as hemoglobin or other cellular proteins or enzymes of red blood cells. These alterations generally protect red blood cells from invasion by Plasmodium parasites or replication of parasites within the red blood cell.

Phosphoglycerate mutase 2 (PGAM2), also known as muscle-specific phosphoglycerate mutase (PGAM-M), is a phosphoglycerate mutase that, in humans, is encoded by the PGAM2 gene on chromosome 7.

References

↑ Lachant NA, Jennings MA, Tanaka KR (1986). "Partial erythrocyte enolase deficiency: a hereditary disorder with variable clinical expression". Blood. 68: 55a.
↑ D'Ancona GG, Chern CJ, Benn P, Croce CM (1977). "Assignment of the human gene for enolase 1 to region pter in equilibrium p36 of chromosome 1". Cytogenetics and Cell Genetics. 18 (6): 327–32. doi:10.1159/000130779. PMID 884968.
↑ Stefanini M (October 1972). "Chronic hemolytic anemia associated with erythrocyte enolase deficiency exacerbated by ingestion of nitrofurantoin". American Journal of Clinical Pathology. 58 (4): 408–14. doi:10.1093/ajcp/58.5.408. PMID 4640298.
1 2 3 Comi GP, Fortunato F, Lucchiari S, Bordoni A, Prelle A, Jann S, Keller A, Ciscato P, Galbiati S, Chiveri L, Torrente Y, Scarlato G, Bresolin N (August 2001). "Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis". Annals of Neurology. 50 (2): 202–7. doi:10.1002/ana.1095. PMID 11506403.
↑ Zhao S, Choy BS, Kornblatt MJ (January 2008). "Effects of the G376E and G157D mutations on the stability of yeast enolase--a model for human muscle enolase deficiency". The FEBS Journal. 275 (1): 97–106. doi:10.1111/j.1742-4658.2007.06177.x. PMID 18070103.

External links

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Lachant NA, Jennings MA, Tanaka KR (1986). "Partial erythrocyte enolase deficiency: a hereditary disorder with variable clinical expression". Blood. 68: 55a.

[2] D'Ancona GG, Chern CJ, Benn P, Croce CM (1977). "Assignment of the human gene for enolase 1 to region pter in equilibrium p36 of chromosome 1". Cytogenetics and Cell Genetics. 18 (6): 327–32. doi:10.1159/000130779. PMID 884968.

[3] Stefanini M (October 1972). "Chronic hemolytic anemia associated with erythrocyte enolase deficiency exacerbated by ingestion of nitrofurantoin". American Journal of Clinical Pathology. 58 (4): 408–14. doi:10.1093/ajcp/58.5.408. PMID 4640298.

[comi-4] 1 2 3 Comi GP, Fortunato F, Lucchiari S, Bordoni A, Prelle A, Jann S, Keller A, Ciscato P, Galbiati S, Chiveri L, Torrente Y, Scarlato G, Bresolin N (August 2001). "Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis". Annals of Neurology. 50 (2): 202–7. doi:10.1002/ana.1095. PMID 11506403.

[5] Zhao S, Choy BS, Kornblatt MJ (January 2008). "Effects of the G376E and G157D mutations on the stability of yeast enolase--a model for human muscle enolase deficiency". The FEBS Journal. 275 (1): 97–106. doi:10.1111/j.1742-4658.2007.06177.x. PMID 18070103.

[1]

[2]

[3]

[4]

[5]